Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10077985 | 0.85 | — | — | |
| SCHEMBL21115556 | 0.82 | CYP2C9 (0.38) | DPP4CYP2C9TSHRCYP2C19TDP1 | |
| SCHEMBL356705 | 0.82 | CYP2C9 (0.38) | DPP4CYP2C9TSHRCYP2C19TDP1 | |
| SCHEMBL23773240 | 0.82 | CYP2C9 (0.38) | DPP4CYP2C9TSHRCYP2C19TDP1 | |
| SCHEMBL22080094 | 0.76 | DPP4 (0.33) | DPP4CYP2C9TSHRCYP2C19TDP1 | |
| SCHEMBL16622504 | 0.74 | — | — | |
| SCHEMBL11040715 | 0.73 | CYP2C9 (0.57) | CYP2C9TSHRCYP2C19TDP1 | |
| SCHEMBL5533014 | 0.73 | — | — | |
| SCHEMBL19578755 | 0.71 | DPP4 (0.32) | DPP4CYP2C9TSHRCYP2C19TDP1 | |
| SCHEMBL2756075 | 0.70 | DPP4 (0.34) | DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. (US) | 2023-11-09 | — | — | US | disclosed |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | Epizyme, Inc. (US) | 2023-06-27 | — | — | US | disclosed |
| US-20220162197-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162197-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | DPP4 3131/4885CYP2C9 4700/4885TSHR 3589/4885 |
| US-20230357208-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | DPP4 3131/4885CYP2C9 4700/4885TSHR 3589/4885 |
| US-11685732-B2 | MYST family histone acetyltransferase inhibitors | EP300, KAT2A, KAT6A | DPP4 3131/4885CYP2C9 4700/4885TSHR 3589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.